Cargando...
Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries
PURPOSE: Novel parenteral (bortezomib) and oral (lenalidomide) therapies have improved survival in myeloma, but the standard Medicare benefit covers only parenteral drugs. We examined the association between prescription drug coverage, receipt of therapy, and survival among Medicare beneficiaries wi...
Guardado en:
| Publicado en: | J Clin Oncol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Clinical Oncology
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6366642/ https://ncbi.nlm.nih.gov/pubmed/30113885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.8894 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|